Curated News
By: NewsRamp Editorial Staff
May 16, 2024
Immunic Highlights IMU-856 Gastrointestinal Candidate to Mark International Celiac Day
TLDR
- Immunic Inc is developing IMU-856, an epigenetic modulator, to treat celiac disease, potentially gaining an edge in the market.
- IMU-856 enhances gut regeneration and strengthens the gut barrier, improving patients' conditions by treating celiac disease at its root cause.
- IMU-856 has the potential to make a significant positive impact on the lives of celiac disease patients, offering a more effective treatment than a gluten-free diet.
- Celiac disease is a severe autoimmune disorder affecting around 1% of the global population, predominantly females, highlighting the importance of raising awareness and advancing treatment options.
Impact - Why it Matters
Celiac disease affects a significant portion of the global population, and the only current treatment is a gluten-free diet, which is not effective for all patients. Immunic's development of IMU-856 offers hope for improving the conditions of celiac disease patients and potentially providing a more effective treatment option.
Summary
Immunic Inc (NASDAQ:IMUX) chief scientific officer Hella Kohlhof discussed the company’s developments in treating celiac disease on International Celiac Day. Celiac disease is a severe autoimmune disorder affecting around 1% of the global population. Immunic is developing IMU-856, an epigenetic modulator, to treat gastrointestinal diseases like celiac disease.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Immunic Highlights IMU-856 Gastrointestinal Candidate to Mark International Celiac Day
